CytoSorbents Investor Relations
CytoSorbents is a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, with more than 300,000 CytoSorb® devices sold in more than 70 countries to date, and seeking U.S. FDA market authorization for an investigational product, DrugSorb-ATR®, to remove blood thinning drugs.
Featured News
CytoSorbents
Press Release
CytoSorbents Reports First Quarter 2026 Financial Results, Recent Business Highlights, and Regulatory Update
PRINCETON, N.J., May 13, 2026 /PRNewswire/ — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today reported financial results for the first quarter ended March 31, 2026, recent business highlights, and provides a regulatory update. First Quarter 2026 Financial Results Revenue ... CytoSorbents Reports First Quarter 2026 Financial Results, Recent Business Highlights, and Regulatory Update
CytoSorbents to Report First Quarter 2026 Financial Results and Recent Business Highlights
PRINCETON, N.J., April 30, 2026 /PRNewswire/ — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report first quarter 2026 financial results and recent business highlights after the market close on Wednesday, May 13, 2026. CytoSorbents’ management will host a ... CytoSorbents to Report First Quarter 2026 Financial Results and Recent Business Highlights
CytoSorbents Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
2025 revenue of $37.1 million, up 4% year-over-year, and 71% Full-year gross margins Enhanced Balance Sheet Flexibility with an Additional $2.5 million Proceeds from Amended Credit Facility in November Implemented Strategic Workforce and Cost Reduction Program in Q4 to Accelerate Timing to Cash Flow Breakeven in 2026 Ongoing Interactive Discussions with FDA to Determine Content ... CytoSorbents Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
CytoSorbents Announces HotSwap™ Launch, Renewed Aferetica Partnership, and New Clinical Evidence at ISICEM 2026
PRINCETON, N.J., March 19, 2026 /PRNewswire/ — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced three major developments at the International Symposium on Intensive Care and Emergency Medicine (ISICEM) this week in Brussels, Belgium – one of the ... CytoSorbents Announces HotSwap™ Launch, Renewed Aferetica Partnership, and New Clinical Evidence at ISICEM 2026
